Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Urology
Published in: BMC Urology 1/2020

01-12-2020 | Fosfomycin | Research article

Cefaclor as a first-line treatment for acute uncomplicated cystitis: a retrospective single-center study

Authors: Dai Koguchi, Yasukiyo Murakami, Masaomi Ikeda, Masato Dobashi, Junichiro Ishii

Published in: BMC Urology | Issue 1/2020

Login to get access

Abstract

Background

Wide-spectrum antibiotics have been favored to treat acute uncomplicated cystitis (AUC) for a long time, leading to the emergence of multi-drug resistant bacteria. We hypothesize that narrow-spectrum antibiotics might mitigate the issue and aim to investigate the clinical efficacy of cefaclor in patients with AUC.

Methods

We retrospectively reviewed the clinical data of female outpatients with AUC treated with cefaclor and evaluated the safety and clinical efficacy. Clinical cure was defined as the elimination of clinical symptom under 4 white blood cells (WBCs) per high power field on microscopy.

Results

Overall, 223 women with AUC were enrolled. Escherichia coli was the dominant pathogen (n = 160; 68.6%), followed by Klebsiella species and E. coli-extended spectrum β-lactamase (ESBL) (n = 19; 8.1% and n = 18; 7.7%). Overall success rate was 94.0% (n = 219) and susceptibility rate of cefazolin was 84.1%, which was close to that of levofloxacin (82.9%). Ampicillin showed the lowest rate of 63.7% with a significantly greater resistance rate of 35.3% among all antibiotics (P < 0.001). In the subgroup analysis, the success rate in patients with resistance to levofloxacin or cefazolin was 100% (n = 24) or 93.3% (n = 14). The rate in patients with resistance to both antibiotics was 60.0% (n = 9), and the pathogens in the other 40.0% (n = 6) of patients with treatment failure were E. coli-ESBL.

Conclusion

Cefaclor showed excellent efficacy in AUC patients, even in those with in vitro resistance to cefazolin or levofloxacin. Cefaclor may be considered as a first-line option in patients with AUC and a second-line option for those with levofloxacin treatment failure.
Literature
1.
Sultan A, Rizvi M, Khan F, Sami H, Shukla I, Khan HM. Increasing antimicrobial resistance among uropathogens: is fosfomycin the answer? Urol Ann. 2015;7(1):26–30.PubMedPubMedCentralCrossRef
2.
Pezzlo M. Laboratory diagnosis of urinary tract infections: guidelines, challenges, and innovations. Clin Microbiol Newsl. 2014;36(12):87–93.CrossRef
3.
Mehnert-Kay SA. Diagnosis and management of uncomplicated urinary tract infections. Am Fam Physician. 2005;72(3):451–6.PubMed
4.
Allen UD, MacDonald N, Fuite L, Chan F, Stephens D. Risk factors for resistance to “first-line” antimicrobials among urinary tract isolates of Escherichia coli in children. CMAJ. 1999;160(10):1436–40.PubMedPubMedCentral
5.
Japanese Association for Infectious Disease/Japanese Society of Chemotherapy, JAID/JSC Guide/Guidelines to Clinical Management of Infectious Disease Preparing Committee, Urinary Tract infection/Male Genital Infection Working Group, et al. JAID/JSC guidelines for clinical management of infectious disease 2015-urinary tract infection/male genital infection. J Infect Chemother. 2017;23(11):733–51.CrossRef
6.
Spellberg B, Doi Y. The rise of fluoroquinolone-resistant Escherichia coli in the community: scarier than we thought. J Infect Dis. 2015;212(12):1853–5.PubMedPubMedCentralCrossRef
7.
8.
van Duin D, Paterson DL. Multidrug-resistant bacteria in the community: trends and lessons learned. Infect Dis Clin N Am. 2016;30(2):377–90.CrossRef
9.
Hayami H, Takahashi S, Ishikawa K, Yasuda M, Yamamoto S, Uehara S, et al. Nationwide surveillance of bacterial pathogens from patients with acute uncomplicated cystitis conducted by the Japanese surveillance committee during 2009 and 2010: antimicrobial susceptibility of Escherichia coli and Staphylococcus saprophyticus. J Infect Chemother. 2013;19(3):393–403.PubMedCrossRef
10.
11.
Santoro J, Agarwal BN, Martinelli R, Wenger N, Levison ME. Pharmacology of cefaclor in normal volunteers and patients with renal failure. Antimicrob Agents Chemother. 1978;13:951–4.PubMedPubMedCentralCrossRef
12.
Etani T, Naiki T, Yamaguchi S, Mori S, Nagai T, Iida K, et al. Antimicrobial susceptibility of pathogens in acute uncomplicated cystitis cases in the urology department of a community hospital in Japan: comparison with treatment outcome and hospital-wide antibiogram. J Infect Chemother. 2017;23(10):692–7.PubMedCrossRef
13.
14.
Doi A, Shimada T, Harada S, Iwata K, Kamiya T. The efficacy of cefmetazole against pyelonephritis caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae. Int J Infect Dis. 2013;17(3):e159–63.PubMedCrossRef
15.
Matsumura Y, Yamamoto M, Nagao M, Komori T, Fujita N, Hayashi A, et al. Multicenter retrospective study of cefmetazole and flomoxef for treatment of extended-spectrum-β-lactamase-producing Escherichia coli bacteremia. Antimicrob Agents Chemother. 2015;59(9):5107–13.PubMedPubMedCentralCrossRef
16.
Fukuchi T, Iwata K, Kobayashi S, Nakamura T, Ohji G. Cefmetazole for bacteremia caused by ESBL-producing enterobacteriaceae comparing with carbapenems. BMC Infect Dis. 2016;16(1):427.PubMedPubMedCentralCrossRef
17.
Chung HC, Lai CH, Lin JN, Huang CK, Liang SH, Chen WF, et al. Bacteremia caused by extended-spectrum-beta-lactamase-producing Escherichia coli sequence type ST131 and non-ST131 clones: comparison of demographic data, clinical features, and mortality. Antimicrob Agents Chemother. 2015;56(2):618–22.CrossRef
18.
Ishikawa K, Matsumoto T, Yasuda M, Uehara S, Muratani T, Yagisawa M, et al. The nationwide study of bacterial pathogens associated with urinary tract infections conducted by the Japanese Society of Chemotherapy. J Infect Chemother. 2011;17(1):126–38.PubMedCrossRef
19.
Matsumoto T, Hamasuna R, Ishikawa K, Takahashi S, Yasuda M, Hayami H, et al. Nationwide survey of antibacterial activity against clinical isolates from urinary tract infections in Japan (2008). Int J Antimicrob Agents. 2008;37(3):210–8.CrossRef
20.
Leigh AP, Nemeth MA, Keyserling CH, Hotary LH, Tack KJ. Cefdinir versus cefaclor in the treatment of uncomplicated urinary tract infection. Clin Ther. 2006;22(7):818–25.CrossRef
21.
Tenney J, Hudson N, Alnifaidy H, Li JTC, Fung KH. Risk factors for acquiring multidrug-resistant organisms in urinary tract infections: a systematic literature review. Saudi Pharm J. 2018;26(5):678–84.PubMedPubMedCentralCrossRef
22.
Alidjanov JF, Naber KG, Abdufattaev UA, Pilatz A, Wagenlehner FM. Reliability of symptom-based diagnosis of uncomplicated cystitis. Urol Int. 2019;102(1):83–95.PubMedCrossRef
23.
24.
Bartoletti R, Cai T, Wagenlehner FM, Naber K, Bjerklund Johansen TE. Treatment of urinary tract infections and antibiotic stewardship. Eur Urol Suppl. 2016;15(4):81–7.CrossRef
25.
Jia H, Li W, Hou T, Ma H, Yang Y, Wu A, et al. The Attributable Direct Medical Cost of Healthcare Associated Infection Caused by Multidrug Resistance Organisms in 68 Hospitals of China. Biomed Res Int. 2019;2019:7634528.
26.
Vallejo-Torres L, Pujol M, Shaw E, Wiegand I, Vigo JM, Stoddart M, et al. Cost of hospitalised patients due to complicated urinary tract infections: a retrospective observational study in countries with high prevalence of multidrug-resistant gram-negative bacteria: the COMBACTE-MAGNET, RESCUING study. BMJ Open. 2018;8(4):e020251.PubMedPubMedCentralCrossRef
27.
Pugliese G, Favero MS. Financial burden of drug resistance in Canada. Infect Control Hosp Epidemiol. 2002;23(11):704.
28.
Ceran N, Mert D, Kocdogan FY, Erdem I, Ozyurek S, Goktas P. A randomized comparative study of single-dose fosfomycin and 5-day ciprofloxacin in female patients with uncomplicated lower urinary tract infections. J Infect Chemother. 2010;16(6):424–30.PubMedCrossRef
29.
30.
Metadata
Title
Cefaclor as a first-line treatment for acute uncomplicated cystitis: a retrospective single-center study
Authors
Dai Koguchi
Yasukiyo Murakami
Masaomi Ikeda
Masato Dobashi
Junichiro Ishii
Publication date
01-12-2020
Publisher
BioMed Central
Published in
BMC Urology / Issue 1/2020
Electronic ISSN: 1471-2490
DOI
https://doi.org/10.1186/s12894-020-00605-6

Other articles of this Issue 1/2020

BMC Urology 1/2020 Go to the issue

Case report

“Sandwich” mesh reconstruction of female giant urethral diverticulum: a case report

Research article

Risk factors for incident delirium among urological patients: a systematic review and meta-analysis with GRADE summary of findings

Research article

Reduction of ureteral stent encrustation by modulating the urine pH and inhibiting the crystal film with a new oral composition: a multicenter, placebo controlled, double blind, randomized clinical trial

Study protocol

Lactobacillus rhamnosus PL1 and Lactobacillus plantarum PM1 versus placebo as a prophylaxis for recurrence urinary tract infections in children: a study protocol for a randomised controlled trial

Research article

Low bone mineral density is a potential risk factor for symptom onset and related with hypocitraturia in urolithiasis patients: a single-center retrospective cohort study

Case report

Metatarsal metastasis from clear cell renal cell carcinoma: a case report and literature review